Evidence supporting the use of: L-carnosine
For the health condition: Parkinson's Disease

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

L-carnosine is a naturally occurring dipeptide composed of beta-alanine and histidine, found in high concentrations in muscle and brain tissues. Its use in supporting or treating Parkinson's Disease (PD) is primarily justified by emerging scientific research rather than tradition. L-carnosine is known for its antioxidant, antiglycation, and neuroprotective properties, which have made it a candidate for mitigating neurodegenerative processes observed in PD.

Several preclinical studies have demonstrated that L-carnosine can reduce oxidative stress and inhibit the aggregation of alpha-synuclein, a pathological hallmark of PD. For example, animal and cell models have shown that L-carnosine supplementation can reduce oxidative damage and protect dopaminergic neurons from degeneration. Its anti-inflammatory effects and ability to chelate metal ions may further contribute to neuroprotection.

However, clinical evidence in humans is limited. A few small pilot clinical studies, mainly from Russian researchers, have reported improvements in some motor and cognitive symptoms when L-carnosine was used as an adjunct to standard PD therapy. These studies suggest potential benefits, but limitations include small sample sizes and lack of widespread replication.

In summary, while there is preliminary scientific evidence supporting the possible neuroprotective effects of L-carnosine in Parkinson’s Disease, the current evidence base is limited and not robust enough to warrant strong recommendations. Larger, well-designed clinical trials are needed to confirm its efficacy and safety in PD patients.

More about l-carnosine
More about Parkinson's Disease

Products containing l-carnosine